Ownership and insider activity for Phio Pharmaceuticals Corp. (PHIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Price
| Price | $1.00 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | BRADFORD PATRICIA A | P-Purchase | 12,000 | $12K |
| 2026-09-11 | Carson Lisa Cabott | F-InKind | 12,888 | $13K |
| 2026-09-11 | Bitterman Robert J | F-InKind | 68,550 | $71K |
| 2026-08-19 | Plott Ronald Todd | P-Purchase | 15,000 | $17K |
| 2026-08-18 | Bitterman Robert J | P-Purchase | 10,000 | $11K |
| 2026-07-20 | Plott Ronald Todd | |||
| 2026-06-26 | Bitterman Robert J | P-Purchase | 10,000 | $10K |
| 2026-02-05 | Lockshin Curtis | A-Award | 16,600 | |
| 2026-02-05 | Freeman Jonathan E | A-Award | 16,600 | |
| 2026-02-05 | Deming David H | A-Award | 23,800 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.9M | $3.6M | $14.9M | $6.9M | $14.2M | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $13.1M | $3.8M | $15.2M | $7.3M | $15.2M | $24.7M | $12.4M | $9.3M | $5.7M | $21.5M |
| Property, Plant & Equipment | $114000 | $248000 | $172000 | $721000 | $557000 | $416000 | $344000 | $39000 | $2000 | $11000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $13.4M | $4.1M | $15.3M | $8.0M | $15.7M | $25.2M | $12.8M | $9.4M | $5.7M | $21.5M |
| Accounts Payable | $917000 | $511000 | $550000 | $809000 | $728000 | $283000 | $779000 | $657000 | $253000 | $435000 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.5M | $2.3M | $1.7M | $1.9M | $2.2M | $3.1M | $1.9M | $1.6M | $1.0M | $435000 |
| Long-term Debt | 0 | 0 | 0 | 0 | $231000 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.5M | $2.3M | $1.7M | $2.3M | $2.7M | $3.2M | $2.0M | $1.6M | $1.0M | $1.3M |
| Retained Earnings | -$66.1M | -$78.6M | -$85.9M | -$94.8M | -$103.6M | -$116.9M | -$128.4M | -$139.2M | -$146.4M | -$155.1M |
| Total Equity | $10.9M | $1.8M | $13.6M | $5.7M | $13.0M | $21.9M | $10.8M | $7.7M | $4.7M | $20.1M |
| Total Debt | 0 | 0 | 0 | $518000 | $642000 | $295000 | $170000 | $35000 | 0 | 0 |
| Net Debt | -$12.9M | -$3.6M | -$14.9M | -$6.4M | -$13.6M | -$23.8M | -$11.6M | -$8.5M | -$5.4M | -$21.0M |
| Working Capital | $10.6M | $1.6M | $13.4M | $5.4M | $13.0M | $21.7M | $10.5M | $7.7M | $4.7M | $21.0M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 15.87 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -7.53 |
Profitability
| Return on Equity | -87.41% |
| Return on Invested Capital | -100.51% |
| Return on Assets | -90.19% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · APRE · APVO · BCDA · CELZ · GLTO · INAB
Explore sector: Healthcare · Biotechnology
More sections of PHIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks